Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge

2024-07-06 4034
(fxcue news) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis. This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements. This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
Sign In via X Google Sign In via Google
This page link:http://www.fxcue.com/27562.html
Tips:This page came from Internet, which is not standing for FXCUE opinions of this website.
Statement:Contact us if the content violates the law or your rights

Please sign in

关注我们的公众号

微信公众号